{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:10:26Z","timestamp":1789017026560,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001592","name":"Higher Education Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jlb.2026.100479","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:18:01Z","timestamp":1782803881000},"page":"100479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2465-8463","authenticated-orcid":false,"given":"Brian D.","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Gately","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Narinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Kanjuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"O\u2019Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras Abu","family":"Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzahra","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Cadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9260-3225","authenticated-orcid":false,"given":"Sharon A.","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15 Pt 1","key":"10.1016\/j.jlb.2026.100479_bib1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.jlb.2026.100479_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jlb.2026.100479_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1016\/j.jlb.2026.100479_bib6","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-Positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jlb.2026.100479_bib7","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jlb.2026.100479_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jlb.2026.100479_bib9","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate Polyclonal acquired clinical resistance to Sacituzumab Govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-020-01797-3","article-title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study","volume":"39","author":"Bon","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jlb.2026.100479_bib11","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","article-title":"Development of an FR\u03b1 companion diagnostic immunohistochemical assay for Mirvetuximab Soravtansine","volume":"148","author":"James","year":"2024","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41698-021-00165-4","article-title":"Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics","volume":"5","author":"Li","year":"2021","journal-title":"npj Precis Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100479_bib13","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1158\/1535-7163.MCT-19-0993","article-title":"Patient selection strategies to maximize therapeutic index of antibody-drug conjugates: prior approaches and future directions","volume":"19","author":"Williams","year":"2020","journal-title":"Mol Cancer Therapeut"},{"issue":"19","key":"10.1016\/j.jlb.2026.100479_bib14","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-Positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jlb.2026.100479_bib15","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jlb.2026.100479_bib16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100479_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/11795549231187264","article-title":"Mirvetuximab soravtansine in platinum-resistant ovarian cancer","volume":"17","author":"Gonzalez-Ochoa","year":"2023","journal-title":"Clin Med Insights Oncol"},{"issue":"19","key":"10.1016\/j.jlb.2026.100479_bib18","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of Anti-Trop-2 antibody drug Conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.jlb.2026.100479_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100479_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Alix-Panabi\u00e8res","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.jlb.2026.100479_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100479_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104263","article-title":"The role of liquid biopsy in epithelial ovarian cancer: state of the art","volume":"194","author":"Della Corte","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41416-025-03227-7","article-title":"Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination","volume":"134","author":"Ward","year":"2026","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100479_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104483","article-title":"Unveiling the impact of circulating tumor cells: two decades of discovery and clinical advancements in solid tumors","volume":"203","author":"Reduzzi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6119","key":"10.1016\/j.jlb.2026.100479_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1228522","article-title":"Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12935-025-04036-x","article-title":"Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer","volume":"25","author":"Bayou","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","article-title":"Efficacy of lapatinib in patients with HER2-Negative metastatic breast cancer and HER2-Positive circulating tumor cells-the DETECT III clinical trial","volume":"70","author":"Fehm","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.jlb.2026.100479_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/BMI.S35075","article-title":"Isolation of circulating tumor cells from multiple epithelial cancers with ApoStream(\u00ae) for detecting (or monitoring) the expression of folate receptor Alpha","volume":"11","author":"O'Shannessy","year":"2016","journal-title":"Biomark Insights"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24180","article-title":"Detection of folate receptor-positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer","volume":"36","author":"Wu","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.jlb.2026.100479_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ces.2025.121983","article-title":"Efficient detection of heterogeneous CTCs using folate modified magnetic beads combined with microfluidic spatial confinement signal amplification","volume":"316","author":"Dong","year":"2025","journal-title":"Chem Eng Sci"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib31","article-title":"TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs","volume":"32","author":"Liao","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100479_bib32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100479_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1935","article-title":"756P first-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23","volume":"34","author":"Konecny","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2026.100479_bib34","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jlb.2026.100479_bib35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10637-020-00995-2","article-title":"A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer","volume":"39","author":"Yam","year":"2021","journal-title":"Invest N Drugs"},{"issue":"4","key":"10.1016\/j.jlb.2026.100479_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"25","key":"10.1016\/j.jlb.2026.100479_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2601563123","article-title":"Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells","volume":"123","author":"Mishra","year":"2026","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.jlb.2026.100479_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-019-1215-z","article-title":"Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial","volume":"21","author":"Jacot","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jlb.2026.100479_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104619","article-title":"Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration","volume":"209","author":"Fusco","year":"2025","journal-title":"Crit Rev Oncol-Hematol"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:32:02Z","timestamp":1789014722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S2950195426000251"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100479","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100479"}}